Media ReleasesImugene Limited

View All Imugene Limited News


Imugene Advances to Phase 2 in Gastric Cancer Immuno-oncology Trial

• Phase 1b study objectives met; all dose levels showed increased antibody levels in all patients

• Phase 2 study on track to start early 2019

• Dose level confirmed for Phase 2 with no safety issues reported

• Phase 2 manufacturing of HER-Vaxx completed

• Topline Phase 1b results expected December 2018

SYDNEY, Australia, 13 November 2018: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company today announced preparations were underway to begin the Phase 2 study of its HER-Vaxx cancer vaccine in gastric cancer patients in early 2019 after completing the Phase 1b study.

A Phase 1b lead-in study tested three doses of HER-Vaxx (IMU-131) in combination with current standard of care chemotherapy (Cisplatin and Fluorouracil or Capecitabine).


For further information please download PDF attached:
Download this document